Rosa Sonja Alesci, MD, health economist, underwent medical training at the Goethe University Hospital Frankfurt, Germany. She started her internal medicine training at Mannheim University Hospital and received her MD at the Ruprecht-Karls-University of Heidelberg. She is currently the director of the IMD blood coagulation centre (Bad Homburg/Frankfurt/Wiesbaden). She deals with one of the biggest cohort of patients with VWD in Germany. She was awarded with the Achieve Program in 2010 and wass the winner of the Hermansky lecture regarding treatment of the VWD also in 2010. Since 2007, she has led and/or developed several investigational clinical trials for patients with bleeding disorders either as study chair, principal investigator or site principal investigator. She is an active member on the „Arbeitskreis Hämostaseologie“ of the German Society of Hematology and Oncology (DGHO) and member of the mecidal advisory board of the „German alliance for security of Hemophilia“. Further, she works unsalaried together with patient organisations. Her activity has been mainly focused on several aspects of clinical research in von Willebrand disease, rare bleeding disorders and ITP. In particular, she is an expert in the question of anticoagulation in patients with haemorrhagic diathesis and in treatment of pregnancy in those patients.

Dr Rosa Sonja Alesci has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Bayer, CSL Behring, Grifols, Novartis, Novo Nordisk, Sobi and Takeda.